Masitinib

DB11526InvestigationalVet approvedSmall molecule

Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. In the...

Chemical structure of Masitinib
Mechanism
Curator reviewed
Formula / weight
C28H30N6OS · 498.65 g/mol (avg)
Also known as
4-((4-METHYLPIPERAZIN-1-YL)METHYL)-N-(4-METHYL-3-((4-PYRIDIN-3-YL-1,3-THIAZOL-2-YL)AMINO)PHENYL)BENZAMIDE
Code names
AB-1010

Resolves to

Compound
UNIIM59NC4E26PCAS790299-79-5ChEMBLCHEMBL1908391ChEBI63450KEGGD10229
Clinical / RWD
ATCL01EX06
Structure
InChIKeyWJEOLQLKVOPQFV-UHFFFAOYSA-NSMILESCN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CS3)C3=CN=CC=C3)=C2)CC1
Targets
P10721KITP22607FGFR3P12931SRC

What you can answer from here — as of September 13, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
39Drug interactionsStructured to mechanism, not free text
Sign in
35Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 8 drug categories
Sign in
27+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Masitinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In